Mid Cap Biotechnology
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
|
ZBIO
76
Zenas BioPharma
ZBIO
$2.2B
| $2.2B | $33.77 | 6.7% |
|
77
Xencor
XNCR
$2.18B
| $2.18B | $29.30 | 1.03% |
|
78
ADMA Biologics
ADMA
$2.18B
| $2.18B | $9.72 | 1.78% |
|
79
Biohaven
BHVN
$2.17B
| $2.17B | $14.38 | 5.12% |
|
80
Stoke Therapeutics
STOK
$2.16B
| $2.16B | $33.46 | 3.53% |
|
|
PVLA
81
Palvella Therapeutics
PVLA
$2.14B
| $2.14B | $148.24 | 1.71% |
|
|
NBTX
82
Nanobiotix
NBTX
$2.11B
| $2.11B | $41.51 | 4.66% |
|
83
Agios Pharmaceuticals
AGIO
$2.02B
| $2.02B | $33.90 | 3.86% |
|
84
Taysha Gene Therapies
TSHA
$2.02B
| $2.02B | $6.20 | 3.85% |
|
Mid Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 84 mid cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $2B and $10B — worth a combined $356B.
The largest by market cap are Protagonist Therapeutics (PTGX) at $9.74B, Spyre Therapeutics (SYRE) at $9.47B and Vaxcyte (PCVX) at $9.09B.
Among institutional investors, Definium Therapeutics (DFTX) drew the most net new fund positions in Q2 2026: 148 funds opened new positions, taking total fund holders up 114 (46%) quarter-over-quarter.
- Combined market cap: $356B across 84 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Protagonist Therapeutics (PTGX), $9.74B market cap.
- Most net new fund positions in Q2 2026: Definium Therapeutics (DFTX), +114 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.